This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Envista Holdings (NVST), Vaxcyte (PCVX)

Tipranks - Tipranks - Fri Aug 7, 4:06AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Envista Holdings (NVST), Vaxcyte (PCVX) and CVS Health (CVS) with bullish sentiments.

Claim 55% Off TipRanks

Envista Holdings (NVST)

William Blair analyst Brandon Vazquez maintained a Buy rating on Envista Holdings today. The company’s shares closed last Wednesday at $28.63.

According to TipRanks.com, Vazquez has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 42.5% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Irhythm Technologies, and Elanco Animal Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Envista Holdings with a $30.00 average price target, which is a 7.3% upside from current levels. In a report issued on July 30, Bank of America Securities also maintained a Buy rating on the stock with a $34.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Vaxcyte (PCVX)

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Vaxcyte, with a price target of $133.00. The company’s shares closed last Wednesday at $55.92.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 20.7% and a 61.9% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Harmony Biosciences Holdings, and Amphastar Pharmaceuticals. ;'>

Vaxcyte has an analyst consensus of Strong Buy, with a price target consensus of $122.20, representing a 122.2% upside. In a report issued on July 29, BTIG also maintained a Buy rating on the stock with a $89.00 price target.

CVS Health (CVS)

In a report released yesterday, Allen Lutz from Bank of America Securities reiterated a Buy rating on CVS Health, with a price target of $120.00. The company’s shares closed last Wednesday at $99.12.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 12.5% and a 67.4% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Hims & Hers Health, and Envista Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $111.31 average price target, a 18.8% upside from current levels. In a report released yesterday, TipRanks – PerPlexity also upgraded the stock to Buy with a $115.00 price target.

Read More on NVST:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).